The efficacy and safety of bevacizumab in addition to platinum‑based chemotherapy for the first‑line treatment of patients with advanced nonsquamous non‑small‑cell lung cancer: Final results of AVALANCHE, an observational cohort study
| Autor: | Áron Kristóf Ghimessy, Edit Csada, György Losonczy, Zsuzsanna Vennes, Zsuzsanna Sztancsik, Edina Tolnay, László Helf, Péter Dombi, Veronika Sárosi, E. Juhasz |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Bevacizumab Population bevacizumab 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Maintenance therapy Internal medicine Clinical endpoint medicine first-line education Lung cancer non-small cell lung cancer education.field_of_study business.industry Articles medicine.disease Carboplatin 030104 developmental biology chemistry 030220 oncology & carcinogenesis Recurrent Lung Adenocarcinoma observational study business Progressive disease medicine.drug |
| Zdroj: | Oncology Letters |
| ISSN: | 1792-1082 1792-1074 0317-0284 |
| DOI: | 10.3892/ol.2018.9766 |
| Popis: | The previous results of former clinical studies confirmed that first-line bevacizumab (BEV) in combination with chemotherapy improves clinical outcomes in patients with advanced non-squamous non-small cell lung cancer. The AVALANCHE study (ClinicalTrials.gov Identifier NCT03170284) was undertaken to assess the clinical outcomes of first-line BEV combined with standard platinum-based regimens in the Hungarian clinical practice. This observational study was conducted in 28 Hungarian sites, with patients enrolled between July 2008 and April 2011. Patients with untreated locally advanced, metastatic or recurrent lung adenocarcinoma received BEV (7.5 mg/kg, q3w) with any platinum-doublet for up to 6 cycles, and then non-progressors proceeded to receive BEV until disease progression or unacceptable toxicity. The primary endpoint was time-to-progression, and secondary endpoints included overall survival (OS), tumour control rate and safety. Patients were also analysed as two cohorts (non-progressors vs. progressors) based on whether or not they received BEV maintenance therapy following completion of first-line chemotherapy plus BEV. The study enrolled 283 patients (median age: 58.2 (18–78) years; males: 50.5%; stage: III/B: 18.4%, IV: 79.9%; adenocarcinoma/other: 95.8/4.2%; ECOG PS 0/1/2/≥3: 30.8/59.7/2.6/1.4%). Centrally located tumours were reported in 21.6%. Cisplatin/carboplatin-based regimens: 53.8/46.2%. A total of 43% of patients received BEV maintenance therapy. The median number of BEV cycles was 6. Median progression-free survival (PFS) was 7.2 months and OS was 15.2 months for the entire cohort. Longer PFS and OS were observed in patients who received BEV maintenance therapy [median OS, 26.2 vs. 10.2 months (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|